| Human mobility and poverty as key drivers of COVID-19 transmission and control M Yechezkel, A Weiss, I Rejwan, E Shahmoon, S Ben-Gal, D Yamin BMC public health 21, 1-13, 2021 | 82 | 2021 |
| BNT162b2 vaccination effectively prevents the rapid rise of SARS-CoV-2 variant B. 1.1. 7 in high-risk populations in Israel A Munitz, M Yechezkel, Y Dickstein, D Yamin, M Gerlic Cell Reports Medicine 2 (5), 2021 | 55 | 2021 |
| Early detection of COVID-19 outbreaks using human mobility data G Guan, Y Dery, M Yechezkel, I Ben-Gal, D Yamin, ML Brandeau PloS one 16 (7), e0253865, 2021 | 31 | 2021 |
| Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study M Yechezkel, M Mofaz, A Painsky, T Patalon, S Gazit, E Shmueli, D Yamin The Lancet Respiratory Medicine 11 (2), 139-150, 2023 | 29 | 2023 |
| Utilizing wearable sensors for continuous and highly-sensitive monitoring of reactions to the BNT162b2 mRNA COVID-19 vaccine Y Gepner, M Mofaz, S Oved, M Yechezkel, K Constantini, N Goldstein, ... Communications Medicine 2 (1), 27, 2022 | 27 | 2022 |
| Self-reported and physiologic reactions to third BNT162b2 mRNA COVID-19 (booster) vaccine dose M Mofaz, M Yechezkel, G Guan, ML Brandeau, T Patalon, S Gazit, ... Emerging Infectious Diseases 28 (7), 1375, 2022 | 26 | 2022 |
| Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study D Yamin, M Yechezkel, R Arbel, T Beckenstein, R Sergienko, ... The Lancet Infectious Diseases 23 (10), 1130-1142, 2023 | 24 | 2023 |
| Tdap vaccination during pregnancy interrupts a twenty-year increase in the incidence of pertussis D Langsam, E Anis, EJ Haas, R Gosinov, M Yechezkel, I Grotto, ... Vaccine 38 (12), 2700-2706, 2020 | 19 | 2020 |
| The rise of SARS-CoV-2 variant B. 1.1. 7 in Israel intensifies the role of surveillance and vaccination in elderly A Munitz, M Yechezkel, Y Dickstein, D Yamin, M Gerlic medRxiv, 2021.02. 16.21251819, 2021 | 15 | 2021 |
| Human mobility and poverty as key factors in strategies against COVID-19 M Yechezkel, A Weiss, I Rejwan, E Shahmoon, SB Gal, D Yamin | 12 | 2020 |
| Optimizing antiviral treatment for seasonal influenza in the USA: a mathematical modeling analysis M Yechezkel, ML Ndeffo Mbah, D Yamin BMC medicine 19, 1-16, 2021 | 8 | 2021 |
| Risk Factors Associated With de Quervain Tenosynovitis in Postpartum Women E Daglan, S Morgan, M Yechezkel, TF Rutenberg, S Shemesh, ... HAND 19 (4), 643-647, 2024 | 5 | 2024 |
| Real-time sensing of war’s effects on wellbeing with smartphones and smartwatches M Mofaz, M Yechezkel, H Einat, N Kronfeld-Schor, D Yamin, E Shmueli Communications Medicine 3 (1), 55, 2023 | 5 | 2023 |
| Safety of COVID-19 Monovalent and Bivalent BNT162b2 mRNA Vaccine Boosters for Adults 60 Years and Above: A Large-Scale Retrospective Study D Yamin, M Yechezkel, R Arbel, T Beckenstein, R Sergienko, ... Available at SSRN 4336133, 2023 | 3 | 2023 |
| A multi-layer model for the early detection of COVID-19 E Shmueli, R Mansuri, M Porcilan, T Amir, L Yosha, M Yechezkel, ... Journal of the Royal Society Interface 18 (181), 20210284, 2021 | 3 | 2021 |
| Utilizing direct and indirect information to improve the COVID-19 vaccination booster scheduling Y Dery, M Yechezkel, I Ben-Gal, D Yamin Scientific Reports 14 (1), 8089, 2024 | 2 | 2024 |
| Risk and early signs of PTSD in people indirectly exposed to October 7 events D Yamin, S Lev-Ari, M Mofaz, R Elias, D Spiegel, M Yechezkel, ... medRxiv, 2023.12. 15.23300048, 2023 | 2 | 2023 |
| Changes in behavior and biomarkers during the diagnostic decision period for COVID-19, influenza, and group A streptococcus (GAS): a two-year prospective cohort study in Israel S Snir, Y Chen, M Yechezkel, T Patalon, E Shmueli, ML Brandeau, ... The Lancet Regional Health–Europe 42, 2024 | 1 | 2024 |
| BNT162b2 Vaccination Effectively Combats the Rapid Rise of SARS-CoV-2 Variant B. 1.1. 7 in High Risk Populations in Israel A Munitz, M Yechezkel, Y Dickstein, D Yamin, M Gerlic Available at SSRN 3796532, 0 | 1 | |
| Incremental benefit of high dose compared to standard dose influenza vaccine in reducing hospitalizations S Yaron, M Yechezkel, D Yamin, T Razi, I Borochov, E Shmueli, R Arbel, ... npj Vaccines 10 (1), 3, 2025 | | 2025 |
